MTOR and neoplasm: Indeed, blocking mTOR with sirolimus (an immunosuppressive agent widely used post LT) and first generation mTORi, has shown promising reduction of HCC tumor growth in preclinical models [9, 10] and in some recent clinical trials [11, 12].